Metrics as of 10/17/2026, 08:41 AM (Berlin time), refresh in progress.
Agios Pharmaceuticals Stock
Agios Pharmaceuticals, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Brian Goff
- Employees
- 540
- Market cap
- $1.9 B
- IPO
- 24/07/2013
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm operating in the Healthcare sector that is dedicated to the research and advancement of new treatments. The company focuses specifically on cellular metabolism and related biological fields. Its product offerings include PYRUKYND (mitapivat), a medication…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
Agios Pharmaceuticals stock: price history
1D
-3.1%
1W
-1.5%
1M
-4.9%
6M
-10.9%
YTD
+15.1%
1Y
-24.6%
2Y
-28.3%
5Y
-32.3%
10Y
-34.4%
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~13% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Agios Pharmaceuticals
Analyst assessment of Agios Pharmaceuticals
PRICE TARGET LOW
US$32.00
CONSENSUS
US$41.33
MEDIAN
US$37.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
22
BUY
7
HOLD
0
SELL
0
STRONG SELL
29
TOTAL · Buy
As of: 07/10/2026
Agios Pharmaceuticals stock metrics
P/E
-4.47
P/B
1.82
EV/EBITDA
-4.32
RETURN ON EQUITY
-9.8%
NET MARGIN
-225.1%
DEBT/EQUITY
0.03
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.6%
FLOAT SHARES
58,254,905
AVG. DAILY VOLUME (30D)
1,092,573
Insider transactions (SEC)
Gheuens Sarah
Backstrom Jay T.
Gheuens Sarah
Gheuens Sarah
Smith Cynthia
Institutional holders
Comparable stocks
Frequently asked questions about Agios Pharmaceuticals stock
What does Agios Pharmaceuticals do?
Agios Pharmaceuticals, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Brian Goff, the company employs around 540 people.
The IPO was on 24/07/2013; the stock trades on NASDAQ under the ticker AGIO.
What do analysts say about Agios Pharmaceuticals stock?
29 analysts rate the stock, the consensus is Buy (as of 07/10/2026).
The average price target is US$41.33, ranging from US$32.00 to US$55.00, with a median of US$37.00.
This is an external assessment, not a statement by Market Jury.
When does Agios Pharmaceuticals report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -13% stronger than usual.
Does Agios Pharmaceuticals pay a dividend?
No, Agios Pharmaceuticals currently does not pay a dividend.
Which stocks are comparable to Agios Pharmaceuticals?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Agios Pharmaceuticals stock analyzed?
Clicking "Analyze stock" lets five strategies assess Agios Pharmaceuticals against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.